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A 53-year-old woman who had undergone total gastrectomy and received adjuvant chemotherapy two months 
ago underwent adhesiolysis of the small bowel. She presented with sudden desaturation and dyspnea of unknown 
etiology at postanesthetic care unit. Following ET intubation, the endotracheal tube suction revealed massive 
hemoptysis. Bilateral lung infiltrated on her chest radiograph and bronchofibroscopic examination disclosed a 
diffuse hemorrhage on both lung fields without bleeding focus. These findings were consistent with diffuse alveolar 
hemorrhage (DAH) syndrome. As per our knowledge and search, this is the first reported case of DAH that occurred 
during the recovery period immediately after general anesthesia. DAH is known to have a high mortality rate and an 
early detection followed by adequate treatment is essential. (Korean J Anesthesiol 2011; 60: 221-225)
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    Diffuse alveolar hemorrhage (DAH) syndrome is caused by 
disruption of the alveolar-capillary basement membrane which 
results in bleeding into the alveolar spaces. There is a sudden 
flow of blood into multiple sites of alveoli and may culminate 
into an acute, life-threatening event. A variety of diseases and 
drugs have been associated with this syndrome [1]. An exposure 
to infectious or toxic agents, systemic vasculitis (e.g., Behcet’s 
syndrome, Henoch-Schoenlein purpura and Wegener’s 
granulomatosis), connective tissue diseases (e.g., Goodpasture’s 
syndrome and systemic lupus erythematosis) and drugs (e.g., 
amiodarone and penicillamine) are well-known etiologic 
factors. DAH is relatively difficult to diagnose and is considered 
potentially fatal. In most cases, the etiology is not always clear, 
even in the event of severe hemorrhage. However, In spite of this 
fact, early intervention of DAH justifies a successful recovery. 
Thus, all the clinicians should be made familiar to DAH in order 
to enable them to arrive at an early diagnosis even during the 
initial examination of the patient.
    We report an unexpected and potentially fatal case of DAH 
that occurred during immediate postoperative period at the 
post-anesthetic care unit, in which a case of massive alveolar 
hemorrhage was managed immediately and successfully. The 
patient underwent adhesiolysis for an hour due to mechanical 
obstruction after the total gastrectomy.222 www.ekja.org
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    A 53-year-old female patient, 161 cm and 46 kg was diagnosed 
with mechanical ileus and admitted for adhesiolysis. She 
underwent total gastrectomy for cancer of stomach 2 months 
ago and had received adjuvant chemotherapy three weeks ago; 
2nd time with S-1 (TS-1
Ⓡ, Jeil Pharmaceutical Co., Ltd, Seoul, 
Korea) 60 mg bid, for 14 days plus cisplatin (Cispuran
Ⓡ, Dong-A 
Pharmaceutical Co., Ltd, Seoul, Korea) 60 mg/m
2 on day 1. 
There was no previous history of cardiopulmonary disease, 
allergies, tuberculosis exposure, or smoking.
    On her visit to emergency room, vital signs of the patient 
were as follows: body temperature, 37.2
oC; heart rate, 106 
beats/minute with a regular rhythm; SpO2, 100% (on room 
air); and blood pressure, 116/86 mmHg. Physical examination 
revealed distended and diminished bowel sounds. Laboratory 
findings on ER were: white blood cell (WBC) count, 3.3 × 103/
mm
3; hemoglobin (Hb), 12.8 g/dl; platelet count, 184 × 103/
mm
3; C-reactive proteins (CRP), 0.56 mg/dl; PT (INR), 1.05 
(normal, 0.8-1.3); and activated PTT, 20.9 sec (normal, 25.0-
35.0). A preoperative chest X-ray, pulmonary function test 
and electrocardiogram were within the normal range. She was 
premedicated by oral midazolam (3.75 mg).
    After the patient was taken to the operating room, she was on 
ECG standard leads II, noninvasive monitors for blood pressure, 
heart rate, arterial oxygen saturation, capnogram, and bispectral 
index. The patient underwent 3 minutes of denitrogenation with 
100% oxygen through a facemask following which 2% propofol 
and remifentanil with the Master target controlled infusion 
was given (Orchestra
Ⓡ Base Primea; Fresenius-MCM GmbH, 
Germany) after administration of lidocaine (40 mg). After 
confirming loss of consciousness, rocuronium (0.5 mg/kg) was 
administered. Endotracheal intubation was then performed 
without any complications. After verifying that patient 
continued to have clear breath sounds in both lung fields, the 
tube was fixed at a depth of 20 cm at the level of incisor teeth. 
The ETCO2 was monitored by capnogram and maintained at 
35-40 mmHg.
    During the operation, 700 ml of Hartmann solution was 
administered. After discontinuing the anesthetics, she began 
to respirate spontaneously. A mixture of glycopyrrolate (0.4 
mg) and pyridostigmine (15 mg) were administered for muscle 
recovery and the endotracheal tube was carefully extubated. 
She was awake fully and had no complaints of any discomfort 
or respiratory disturbance except for the surgical site pain, and 
she was therefore transported to the post anesthetic care unit. 
Oxygen at 5 L/min was administered through a Venturi mask 
when the pulse oximetry indicated a SpO2 of 97%.
    Fifteen minutes after extubation, the pulse oximeter 
indicated SpO2 of 70%. A sudden onset of dyspnea and 
hemoptysis developed. The patient was promptly intubated 
and approximately 50 ml of fresh blood was suctioned through 
the endotracheal tube. A bronchoscopy was immediately per-
formed to determine the cause of hemoptysis and hypoxia. The 
apparent bleeding was localized to originate from right upper 
lobe in the beginning, but the bleeding continued to become 
bilaterally with no identifiable bleeding focus (Fig. 1). The chest 
radiograph revealed bilateral diffuse alveolar infiltrates (Fig. 2). 
Arterial blood gas analysis after endotracheal intubation and 
mechanical ventilator applied were: arterial oxygen tension 
(PaO2), 55 mmHg; arterial carbon dioxide tension (PaCO2), 47 
mmHg; pH, 7.31; Hb, 10.5 g/dl.
    The patient was transferred to the intensive care unit (ICU) 
due to her unstable vital signs. The vital signs measured upon 
arrival showed a blood pressure of 80/50 mmHg, heart rate 
of 162/min and SpO2 of 90% and Swan-Ganz catheter was 
inserted. The blood test results revealed the following: Hb, 8.7 
g/dl; hematocrit, 26%; platelet count, 57,000/mm
3; WBC count, 
Fig. 1. Fiberoptic bronchoscope showed the generally diffuse fresh blood at bronchial trees.223 www.ekja.org
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900/mm
3; absolute neutrophil, 640/mm
3. The PT was 19.8 sec 
and the activated PTT was 37.1 sec. The vasopressor drugs such 
as dopamine, norepinephrine and vasopressin were infused 
to stabilize the blood pressure and hydrocortisone (300 mg) 
was injected. Five units of packed RBCs, 6 units of fresh frozen 
plasmas and 10 units of platelets were transfused for 7 hours. A 
bronchoscope was performed again at the ICU by pulmonologist 
after the vital signs were stable. The bronchoscopy revealed 
presence of alveolar hemorrhage in both lungs and no focal 
bleeding sources again. Urinary analysis with microscope and 
serologic laboratory were checked.
    Five days after the intubation, the patient sufficiently 
recovered and subsequently mechanical ventilation was dis-
continued. On the postoperative day 6, there was no evidence 
of alveolar hemorrhage by bronchoalveolar lavage (BAL). 
Bilateral infiltration resolved and confirmed by high resolution 
computed tomography (HRCT) scan images (Fig. 3). The patient 
became symptom-free and was discharged from the hospital 20 
days after the surgery. S-1 was excluded from the chemotherapy 
regimen in this patient and no recurrences of symptoms were 
observed after discharge.
Discussion
    The term ‘diffuse alveolar hemorrhage’ refers to a distinct form 
of pulmonary hemorrhage that originates from the pulmonary 
microcirculation including alveolar capillaries, arterioles, and 
venules [1]. It is also known by names such as intrapulmonary 
hemorrhage, diffuse pulmonary hemorrhage, pulmonary 
alveolar hemorrhage, pulmonary capillary hemorrhage, 
alveolar bleeding, or microvascular pulmonary hemorrhage 
[2]. Dyspnea, cough, hemoptysis, and new alveolar infiltrates in 
conjunction with bloody BAL establish the diagnosis of DAH.
    DAH can occur in association with various drugs and a 
wide variety of clinical disorders, many of which have over-
lapping features of glomerulonephritis, immune complex, 
and antiglomerular basement membrane disease [1]. Since 
the serological investigations and renal ultrasound were 
unremarkable for immune or renal disease in our case, together 
with the careful exclusion of these causes, several elements 
led to the suspicion that her lung damage was an expression of 
drug-induced adverse reaction.
    Drug-induced lung injury may represent three mechanisms 
such as an immune or hypersensitivity reaction, an injury to the 
alveolar capillary basement membrane, or a coagulation defect 
[3]. In this case, there was no clinical or laboratory evidence 
of vasculitis and preoperative thrombocytopenia. We suspect 
that the drug may have a role to play in causing DAH [3] in this 
Fig. 2. Preoperative chest PA film 
appeared within normal limits (A) but 
postoperative chest AP view de  mon-
strated the bilateral diffuse patchy 
infiltrates (B).
Fig. 3. Chest CT scan taken 1 week after the hemoptysis episode 
demonstrated multifocal minimal fibrosis and ground glass opacities 
to be regarded as fibrotic sequel of nonspecific inflammation.224 www.ekja.org
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patient. The patient’s manifestation of DAH in the setting of 
total gastrectomy and adjuvant chemotherapy raises a question 
of the possible predisposition of drug toxicity by cytotoxic drugs.
    A majority of anti-neoplastic drugs have the potential to 
induce pulmonary toxicity, involving lung parenchyma, airways, 
pleura, and pulmonary circulation [4]. S-1 is a recently approved 
oral anti-neoplastic agent containing prodrug 5-FU that has 
been a first line drug in the therapy of gastrointestinal cancers 
[5]. The major adverse effects of S-1 documented and reported 
so far are hematological and gastrointestinal nature. There are 
a few reports of pulmonary complication of S-1 available. S-1 
and other cytoxic agents, 5-FU, have been reported to cause the 
interstitial lung disease which may be resolved by corticosteroid 
[6-8]. Thus, increasing the probability of DAH to be caused by 
S-1, although the exact component of the drug that is implicated 
was not identified by drug lymphocyte stimulation test (DLST) 
[4,9]. As far as the pathogenesis is concerned, a positive DLST 
result on 5-FU does not always automatically cause lung 
injuries. It seems that the direct toxic effect of the drugs on the 
parenchymal structures is responsible for the lung injuries 
rather than that of immunologically-driven mechanisms.
    For these experiences it becomes extremely important to 
obtain a full treatment history in all patients who manifest 
diffuse pulmonary infiltrates. Despite these findings, the timing 
of the drug administration in relationship to the development of 
this complication points to its role in the causation of the event. 
However, it is reported that the pulmonary effects of cytotoxic 
drugs, such as bleomycin or mitomycin, occurs several months 
following completion of therapy [10]. The use of oxygen in high 
concentrations during an unrelated surgery in a patient who 
was treated previously with bleomycin, and, possibly, other 
cytotoxic drugs, can result in an acute pulmonary syndrome 
years after the initial drug exposure [11,12].
    Another drug that we could not exclude our suspicion, 
according to the timing of administration, is propofol, though 
such toxicity has not been reported previously in the literature. 
The patient underwent total gastrectomy 3 months ago with 
same anesthetic method and total infused dose of propofol 
was twice more than that of this instance. In the endotoxic rat 
model, pretreatment and simultaneous treatment with propofol 
provided protection against acute lung injury by inhibiting the 
TGF-beta1-Smad2 dependent pathway [13].
    Transbronchial lung biopsy was intentionally not performed 
in our patient because of the characteristic finding of DAH (i.e. 
progressively diffuse hemorrhage) in the beginning. Also, the 
need for mechanical ventilation and the severity of respiratory 
failure precluded us from obtaining the biopsy at that point 
of time. Performing a surgical lung biopsy, although useful 
in confirming DAH, is generally not suitable to identify the 
underlying causes [14].
    DAH is always a potentially life-threatening situation. 
Consequently, the first goal in the management of patients with 
DAH is to achieve or preserve stability of the respiratory status. 
An urgent bronchoscopy is recommended in patients whose 
diagnosis is uncertain. A possible management protocol should 
include supplemental oxygen, bronchodilators, reversal of 
any coagulopathy, intubation, protective strategies for the less 
involved lung, and mechanical ventilation. If therapy targets 
the autoimmune destruction of alveolar capillary membrane 
and the coexisting autoimmune condition, the application 
of corticosteroids and immunosuppressive agents should be 
considered.
    This case report describes the unexpected hemoptysis 
following surgical procedures in patients who underwent 
recent chemotherapy. This uncommon complication should 
be considered in the differential diagnosis of unknown etiology 
of hypoxia during peri-operative periods. The prevalence of 
this form of pulmonary hemorrhage in patients receiving S-1 
chemotherapy is unclear at this time. However, several clinical 
cases describing such diffuse interstitial pulmonary injury have 
been reported.
    The objective of this write-up is to prime the clinicians on 
this occurrence and to increase the awareness of the fact that 
S-1 has the potential to cause lung injury when it is included in 
chemotherapy. Furthermore, the patients' medication history 
should be taken into a careful consideration for perioperative 
evaluation especially in patients with pulmonary complications.
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